Audit: QRS - Pelvic Floor Therapy for Health & Longevity
Audit conducted on 11/09/2026 02:56 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 81 |
| Failed | 0 |
| N/A | 12 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values (3 sets of 8–12, 6–8 s holds, 10–20 daily, 6 appointments/16 weeks), all monitoring targets, all benefit and risk items, and all gate items trace to ER lines 311–341, 364–368, 419, 451–472. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No empty-state or hedged ER phrasing is restated; tiering carries the certainty, as the ER does. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication scope qualifiers (“as sole therapy”, “for internal techniques”, “for unsupervised protocols”) are carried at ER strength. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs or brand names. The only expert name, “The Bø protocol”, appears in ER line 364 for the same fact. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution beyond the ER-sourced Bø protocol reference. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Declarative, measured, mechanism-aware register matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | “Strongest returns:” framing in the lede is positive without overclaiming; targets and cadence are concrete. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells are noun phrases describing what trials used, not instructions issued to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives; no “should”, “must”, “recommend” or “advise” anywhere in the body. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | E.g. “the dose used in the largest trials”, “The point at which symptom endpoints are assessed in trials”. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs anywhere in the document body. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | The lede renders the technical terms plainly (“the coordination fault behind stubborn constipation”, “pelvic organs sagging”); the remaining technical terms are instrument and drug-class names that cannot be replaced without losing the fact. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are stripped to the key fact; the monitoring table drops the ER’s Context/Notes column entirely. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address on any surface. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Ten monitoring markers with numeric targets and a maintenance cadence assume a reader who will measure and track. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A 12–16-week daily protocol plus 6 supervised appointments is presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified “just do Kegels” framing; assessment-before-loading is made the gating step. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede names the asymmetry that matters to this audience — prevention before childbirth over treatment after, and the tight-floor error. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not appear; the title carries “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial register anywhere; drug classes are named formally (antimuscarinics, beta-3 adrenergic agonists, serotonin-noradrenaline reuptake inhibitors). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings match the template byte-for-byte (lines 446, 493, 543, 577, 610, 645, 670, 674–676, 804 and the four tier labels in each of the Benefits and Risks cards). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables are present; the repeatable marker_#_* and qualitative_item_# patterns are instantiated as marker_1–10 and qualitative_item_1–7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows changes only inside variable spans and the metadata block; all CSS, comments, classes and static markup are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped to the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Core strengthening protocol”, “The knack, trained separately” and “Supervision schedule” are the ER’s bold labels verbatim (ER lines 364, 366, 368). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol labels are verbatim; monitoring row labels are the ER biomarker names verbatim; the time-to-effect labels name the three clauses of the single ER “Time to effect” bullet. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s tier emoji and the “⚠️ Conflicted” markers are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: gate items are stripped of the ER’s mechanism and mitigation clauses, benefit and risk items reduced to bare tier headings, and the monitoring table drops the ER’s entire Context/Notes column. No section is carried over verbatim and no section is duplicated or extended. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14: the comment opens on line 2, immediately after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3, closing “—” on line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly, because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: pelvic_floor_therapy_2026-0911-0003_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0911-0242. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual filename on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine values are trimmed; quoting is used only where YAML requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Pelvic Floor Therapy for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Pelvic Floor Therapy for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/11/2026” from qrs_creation_date 2026-0911-0242. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 498–500: strongest-return outcomes, the prevention-over-treatment asymmetry, and the tight-floor error with assessment as the gate. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct clause of the ER Conclusion (lines 498 and 500). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “dyssynergic defecation” is rendered as “the coordination fault behind stubborn constipation” and “pelvic organ prolapse” as “the sensation of pelvic organs sagging”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from the ER “Populations who should avoid Pelvic Floor Therapy” list, lines 333–340. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER entries are present, in ER order, with none added or dropped. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the span, lines 580–605. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dash-trailing clauses; the ER’s explanatory tails are stripped (e.g. “where symptom relief from muscle training alone is not a realistic endpoint” removed from the stage IV item). Remaining “for …” phrases are scope conditions of the gate, not explanations. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “6 weeks” windows, “third- or fourth-degree”, “stage IV (complete eversion)”, “before 37 weeks” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is not empty; the ER names eight avoid-conditions. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items come from the ER interaction bullets, lines 311–329. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten ER interaction bullets are present in ER order; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Ten <li> elements inside the span, lines 613–635. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item is reduced to the ER’s bold label plus its parenthetical drug list; every “Caution”, “Additive benefit”, mechanism and “Mitigation:” clause is stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example drugs preserved, including the “above 1,000 mg” vitamin C threshold. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is not empty; the ER names ten interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | The three cells map to ER “Therapeutic Protocol” bullets at lines 364, 366 and 368. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Core strengthening dose, the knack, and supervision schedule — the three executable bullets; the remaining ER bullets are attribution, competing approaches and modifier notes. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content; values are the quantified dose (3 sets of 8–12 daily, 10–20 times daily, 6 appointments over 16 weeks). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Symptom endpoints, prolapse and pain outcomes, and motor control/strength — the three clauses of ER line 419. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Symptom endpoints first (the High-tier leakage outcome), then prolapse and pain (also High tier), then the process measures of motor control and strength. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Values 12–16 weeks, up to 12 months and 2–4 weeks all match ER line 419. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All thirteen items are the ER benefit sub-headings, lines 151–231. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated, lines 545–570. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; no magnitude line, mechanism or citation is carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefit item; the “⚠️ Conflicted” markers on two Low-tier headings are correctly dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER (5 / 4 / 3 / 1). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six items are the ER risk sub-headings, lines 255–293. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated, lines 647–664. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; the frequency figures (66 of 1,083, 44% uncured) are correctly absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers have items in the ER (2 / 1 / 2 / 1). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows map one-to-one to the ER “Monitoring Protocol & Defining Success” table, lines 453–462. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarkers are present in ER order, with the Optimal Functional Range and Why Measure It? columns carried verbatim and the Context/Notes column dropped. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 794–798 condense ER lines 447 and 449: baseline first, then 4 weeks, 12 weeks, 6 months, 6–12 monthly; objective strength at 12 weeks and annually. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items come from the ER “Qualitative markers tracked alongside the numbers” list, lines 466–472. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers are present verbatim and in ER order. |
Issues 11/09/2026 02:56
Pass rate 100.00%. No issues found.
Issues 11/09/2026 02:48
- 1.1 — Time-to-effect claim not in ER: [time_1_sub] (QRS lines 505-508) states that the 12-16 week symptom-endpoint window includes “leakage on effort”, but ER line 419 says only “symptom endpoints in trials are assessed at 12 to 16 weeks” and never ties that window to a named outcome.
Fixes 11/09/2026 02:48
- 1.1 — Unsupported time-to-effect detail: Trimmed [time_1_sub] from “The point at which symptom endpoints are assessed in trials, including leakage on effort.” to “The point at which symptom endpoints are assessed in trials.”, matching ER line 419.